- Trials with a EudraCT protocol (124)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
124 result(s) found for: Adiposity.
Displaying page 5 of 7.
EudraCT Number: 2008-008141-37 | Sponsor Protocol Number: diab123v1.0 | Start Date*: 2009-09-08 | ||||||||||||||||
Sponsor Name:Sherwood Forest Hospitals Foundation Trust | ||||||||||||||||||
Full Title: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study | ||||||||||||||||||
Medical condition: sleepiness and lethargy among obese patients with diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003432-39 | Sponsor Protocol Number: D1690L00016 | Start Date*: 2014-11-19 | |||||||||||
Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University | |||||||||||||
Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e... | |||||||||||||
Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001628-45 | Sponsor Protocol Number: 2.0 | Start Date*: 2015-09-09 |
Sponsor Name:Dep. of Medical Cell Biology Uppsala University | ||
Full Title: A parallel, double-blinded, randomized, 6 months, two arms study with lifestyle intervention and exenatide 2 mg once weekly or lifestyle intervention and placebo in adolescents with obesity to expl... | ||
Medical condition: Obesity in adolescents | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-010198-19 | Sponsor Protocol Number: CLCQ908A2204 | Start Date*: 2009-05-27 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL ch... | ||||||||||||||||||
Medical condition: Obesity and mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Completed) ES (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021268-13 | Sponsor Protocol Number: Letrozole2010-1 | Start Date*: 2010-11-19 | ||||||||||||||||
Sponsor Name:University College Dublin | ||||||||||||||||||
Full Title: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial | ||||||||||||||||||
Medical condition: Obesity Related Male Hypogonadism | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004554-34 | Sponsor Protocol Number: 2014-004554-34 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001661-91 | Sponsor Protocol Number: ML19569 | Start Date*: 2016-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | ||||||||||||||||||
Full Title: Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents | ||||||||||||||||||
Medical condition: Obesity in combination with metabolic disorders | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007970-47 | Sponsor Protocol Number: fMRI-Ex-4 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study | ||||||||||||||||||
Medical condition: Obesity (N=20) vs. obesity with type 2 diabetes (N=20); Randomised + controlled + cross-over + prospective + double-blind + stratified + 2 arms: Exendin-4 vs NaCl 0.9% iv ober 100 minutes on two s... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000652-14 | Sponsor Protocol Number: L00085 CP 403 | Start Date*: 2007-09-28 | ||||||||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | ||||||||||||||||||
Full Title: Etude en double aveugle versus placebo de l’efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses | ||||||||||||||||||
Medical condition: femmes âgées de plus de 18 ans dont le consentement éclairé écrit a été obtenu, affiliées à un régime de sécurité sociale française, non susceptibles d’être enceinte ou de l’être au cours de l’étud... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006305-25 | Sponsor Protocol Number: 2007-006305-25 | Start Date*: 2008-02-15 | ||||||||||||||||
Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
Full Title: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome | ||||||||||||||||||
Medical condition: Obese adults with Prader Willi Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002407-10 | Sponsor Protocol Number: 17/0238 | Start Date*: 2018-03-23 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery. | ||||||||||||||||||
Medical condition: Obesity. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-009278-29 | Sponsor Protocol Number: S51477 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||||||||||||
Full Title: Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen | ||||||||||||||||||||||||||||
Medical condition: Neuromuscular and neurological diseases, associated with obesity and insulin resistance | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002805-88 | Sponsor Protocol Number: J2A-MC-GZGI | Start Date*: 2021-09-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities | |||||||||||||
Medical condition: Obesity and Overweight with Weight-Related Comorbidities | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000082-72 | Sponsor Protocol Number: RC-P0054 | Start Date*: 2019-01-03 | |||||||||||
Sponsor Name:Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL) | |||||||||||||
Full Title: Study of the communication of the hypothalamus with the periphery: impact of metformin on leptin transport in the cerebrospinal fluid of obese patients. A monocentric prospective study | |||||||||||||
Medical condition: OBESITY (BMI > 30) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004452-42 | Sponsor Protocol Number: STABIL-NOR | Start Date*: 2022-12-14 | |||||||||||
Sponsor Name:Helse Bergen HF | |||||||||||||
Full Title: An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR –... | |||||||||||||
Medical condition: Drug induced weight gain from anti-psychotic drug treatment in patients with schizophrenia. Treatment with semaglutide, a glucagon-like peptide receptor agonist used to treat diabetes and approv... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005317-40 | Sponsor Protocol Number: Herlev | Start Date*: 2021-05-27 |
Sponsor Name:Odense University Hospital - Department of Cardiology | ||
Full Title: Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): A randomized controlled trial | ||
Medical condition: Obese patients (BMI >28 kg/m2), aged 60-84 years, with documented cardiovascular disease but no history of diabetes mellitus or heart failure with reduced ejection fraction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006534-40 | Sponsor Protocol Number: NN9932-4954 | Start Date*: 2022-09-21 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4) | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002235-60 | Sponsor Protocol Number: NN9536-7545 | Start Date*: 2023-02-24 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) SK (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006772-38 | Sponsor Protocol Number: R256918OBE2001 | Start Date*: 2007-10-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) NL (Completed) GB (Completed) SE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002868-14 | Sponsor Protocol Number: CLIK066B2201 | Start Date*: 2017-04-18 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee... | ||||||||||||||||||
Medical condition: change in weight in obese or overweight adults | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
